Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3739898 | 0.93 | SIRT2 (0.40) | SIRT2SIRT1SIRT3TLR2MBOAT4 | |
| SCHEMBL3727029 | 0.92 | SIRT2 (0.39) | SIRT2SIRT1SIRT3MBOAT4CAPN1 | |
| SCHEMBL3729930 | 0.90 | CTSD (0.39) | SIRT2SIRT1SIRT3MBOAT4CAPN1 | |
| SCHEMBL3730584 | 0.77 | PRKCA (0.52) | SIRT2SIRT1SIRT3TLR2CTSL | |
| SCHEMBL3740450 | 0.77 | TLR2 (0.46) | SIRT2SIRT1SIRT3TLR2MBOAT4 | |
| SCHEMBL3734137 | 0.76 | TLR2 (0.49) | SIRT2SIRT1SIRT3TLR2CTSL | |
| SCHEMBL3725744 | 0.76 | CTSK (0.54) | CTSLCTSSMEN1KMT2ACTSK | |
| SCHEMBL3731672 | 0.76 | CTSK (0.54) | CTSLCTSSMEN1KMT2ACTSK | |
| SCHEMBL3734259 | 0.75 | TLR2 (0.46) | SIRT2SIRT1SIRT3TLR2CTSL | |
| SCHEMBL10576623 | 0.73 | SIRT2 (0.59) | SIRT2SIRT1SIRT3CTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825238-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2010-11-02 | — | — | US | disclosed |
| US-7071173-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | MEDIVIR AB (SE) | 2006-06-08 | — | — | US | disclosed |
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | MEDIVIR AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-6974802-B2 | Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine | MEDIVIR AB (SE) | 2005-12-13 | — | — | US | disclosed |
| US-6458772-B1 | Prodrugs | MEDIVIR AB (SE) | 2002-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | UNG, HAVCR2, EIF2AK2 | SIRT2 2519/4885SIRT1 3697/4885SIRT3 3150/4885 |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | UNG, HAVCR2, EIF2AK2 | SIRT2 2519/4885SIRT1 3697/4885SIRT3 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.